Sara Deola, MD, PhD

Investigator Cell and Gene Therapy Specialist
Advanced Cell Therapy Core

Email: sdeola@sidra.org or sdeola1@sidra.org
Phone: +974 40037553

Biography

Dr. Deola is a clinical scientist with a Board Certification in Hematology-Oncology from University San Raffaele Vita-Salute, Milan, Italy and a PhD in Experimental Hematology from the University of Milan Bicocca, Italy (training at Telethon Institute for GenE Therapy, TIGET). Her research focus during PhD was on gene transfer in Hematopoietic Stem Cells.

Her clinical training was at the BMT Unit of Hospital San Raffaele, and she worked 5 years as staff physician in the Hematology and BMT Department of the General Hospital of Bolzano, Italy, mostly following allogeneic HSCT patients.
She joined Sidra Medicine in 2014, as Bone Marrow Transplant Program Manager in Translational Medicine/Research, and she is holding a PI position since June 2017 in the Advanced Cell Therapy Core.
Research Interests

Her clinical training was at the BMT Unit of Hospital San Raffaele, and she worked 5 years as staff physician in the Hematology and BMT Department of the General Hospital of Bolzano, Italy, mostly following allogeneic HSCT patients. She joined Sidra Medicine in 2014, as Bone Marrow Transplant Program Manager in Translational Medicine/Research, and she is holding a PI position since June 2017 in the Advanced Cell Therapy Core.

Activities currently range from Hematopoietic Stem Cells processing, as part of the Bone Marrow Transplantation clinical program, to several projects of cell therapy (i.e. production of mesenchymal stromal cell from different sources), gene therapy (i.e. anti-tumor engineered Chimeric Antigen Receptor T-cells) and regenerative medicine (i.e. production of platelet rich plasma, platelet rich fibrin, adipose-derived stem cells and cell-drug codelivery).

Within the Core, Sara Deola is leading research projects on:

• Graft-versus-host disease after allogeneic Hematopoietic Stem Cell Transplantation (immunology and transcriptomics);

• B-T cell lymphocyte interactions in Graft-versus-host disease;

• Gene therapy of Hematopoietic Stem Cells in Hemophilia;

And she is involved in a project on:

• Acute leukemias (genetics, epigenetics, proteomics)
Lab Members

https://orcid.org/0000-0002-3178-1271

Elnaggar M, Al-Mohannadi A, Kizhakayil D, Raynaud CM, Al-Mannai S, Gentilcore G, Pavlovski I, Sathappan A, Van Panhuys N, Borsotti C, Follenzi A, Grivel JC, Deola S. “Flow-Cytometry Platform for Intracellular Detection of FVIII in Blood Cells: A New Tool to Assess Gene Therapy Efficiency for Hemophilia A”. Mol Ther Methods Clin Dev. (2019) Nov 15;17:1-12.
Deola S*, Cugno C, Comoli P, Guido I, Rubert L, Zecca M, Zanolini D, Follenzi A, Langes M, Negri G, Tauber M, Pusceddu I, Cavattoni I, Svaldi M, Wang E, Rutella S, and Marincola FM. “Evidence for CD19B-CD8T Cell Interactions in Blood and Tissues from Patients with Graft-Versus-Host Disease.” Bone Marrow Transplant (2017) 52(3):459-462.
Deola S, Panelli MC, Maric D, Selleri S, Dmitrieva NI, Voss CY, Klein H, Stroncek D, Wang E, Marincola FM. “Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions”. J Immunol. (2008) Feb 1;180(3):1362-72.

Sara Deola, MD, PhD

Investigator Cell and Gene Therapy Specialist Advanced Cell Therapy Core

Biography

Research Interests

Lab Members

Investigator Cell and Gene Therapy Specialist
Advanced Cell Therapy Core